The Commission on Human Medicines (CHM) is the Government\u2019s scientific advisory committee, from which the Medicines and Healthcare products Regulatory Agency (MHRA) seeks independent scientific advice.<\/p>
<\/p>
The CHM considered a thorough review of the safety of human papillomavirus (HPV) vaccine at its meeting on 16 July 2015. Prior to 2015, the CHM considered reviews of HPV vaccine at meetings in September 2012, September 2010, September 2009, June 2009 and February 2009. These reviews included evaluation of United Kingdom Yellow Card reports, analysis of data from the Clinical Practice Research Datalink (CPRD), published safety studies and safety data from other countries.<\/p>
Most recently, the CHM considered the safety of HPV vaccine at its meeting on 15 October 2015. At this meeting, the MHRA sought advice from the CHM on the (Co)-Rapporteurs\u2019 assessment reports prepared for the European Medicines Agency (EMA) review into reports of postural orthostatic tachycardia syndrome and complex regional pain syndrome following HPV vaccine, in order to inform the UK position in the review.<\/p>
<\/strong>As with all vaccines and medicines, the safety of HPV vaccine remains under continual review by the MHRA.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-04T16:04:46.43Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-26", "_datatype" : "dateTime"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government, further to the Written Answer by the Parliamentary Under-Secretary of State, Department of Health, on 24 April (HC70973), when and how the Commission on Human Medicines \"thoroughly review the data\" on human papilloma virus (HPV) vaccine adverse reactions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
}
, "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
], "uin" : "HL182"}
, {"_about" : "http://data.parliament.uk/resources/732745", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/732745/answer", "answerText" : {"_value" : " The European Medicines Agency (EMA) concluded a thorough review of reports of postural orthostatic tachycardia syndrome (POTS) following human papillomavirus (HPV) vaccine in November 2015, which found that the evidence did not support a causal association between HPV vaccination and POTS.<\/p> <\/p> As of 26 June 2017, the Medicines and Healthcare products Regulatory Agency (MHRA) has received 60 reports of POTS following HPV vaccine via the Yellow Card Scheme. More than three million girls have been vaccinated against HPV since 2008 across the United Kingdom, and the MHRA\u2019s evaluation remains that the number of reports does not exceed what would be expected to occur in the absence of HPV vaccine and that the evidence does not suggest a causal association with the vaccine.<\/p> <\/p> The MHRA does not currently propose to ask the EMA to conduct a further review. As with the safety of all vaccines and medicines, this issue will remain under review.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-07-03", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-03T16:44:42.64Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-26", "_datatype" : "dateTime"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government whether, in the light of the significant increase in the number of cases of postural orthostatic tachycardia syndrome (POTS) reported as an adverse reaction to HPV vaccination since July 2015, they will ask the European Medicines Agency to review the safety signal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
}
, "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
], "uin" : "HL183"}
, {"_about" : "http://data.parliament.uk/resources/732746", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/732746/answer", "answerText" : {"_value" : " The Commission on Human Medicines (CHM) is the Government\u2019s scientific advisory committee, from which the Medicines and Healthcare products Regulatory Agency (MHRA) seeks independent scientific advice.<\/p> <\/p> Following a review of human papillomavirus (HPV) vaccine safety on 16 July 2015, the CHM advised the MHRA that the available evidence does not support a causal association between HPV vaccination and development of postural orthostatic tachycardia syndrome (POTS) or complex regional pain syndrome (CRPS), as well as other chronic illnesses. The public minutes of this meeting were made available online on 18 November 2015.<\/p> <\/p> At its meeting on 15 October 2015, the MHRA sought advice from the CHM on the (Co)-Rapporteurs\u2019 assessment reports prepared for the European Medicines Agency (EMA) review into reports of POTS and CRPS following HPV vaccine, in order to inform the United Kingdom position in the review. The public minutes of this meeting were made available online on 21 December 2015.<\/p> <\/p> The CHM did not make a statement in October in advance of the EMA\u2019s Scientific Advisory Group meeting. The CHM\u2019s minutes were published on the above dates in line with usual practice and have informed the MHRA\u2019s responses to enquiries about the safety of HPV vaccine.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-04T16:05:33.797Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-26", "_datatype" : "dateTime"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government who advised the Commission on Human Medicines that the available evidence does not support a causal association between HPV vaccination and development of postural orthostatic tachycardia syndrome (POTS) or complex regional pain syndrome (CRPS) according to the Commission's minutes of 15\u201316 October 2015; and why this statement was made before the European Medicines Agency Scientific Advisory Group (SAG) reported on 21 October 2015.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
}
, "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
], "uin" : "HL184"}
, {"_about" : "http://data.parliament.uk/resources/732080", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/732080/answer", "answerText" : {"_value" : " Skills for Care workforce data shows that there were 90,335 vacant posts in the adult social care sector. This equates to a vacancy rate of 6.8%. This data is as at March 2016 for the independent sector and September 2015 for statutory local authorities.<\/p> <\/p> Current vacancies, in addition to demographic changes in the population and raised expectations mean there will be an increasing demand on care services in the future, including from the elderly and disabled. Skills for Care, an employer-led workforce development organisation for adult social care, is looking to address this through their recruitment and retention strategy.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-07-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-05T12:18:53.053Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-22", "_datatype" : "dateTime"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government how many vacancies exist in the social care sector in England; and what assessment they have made of the impact of those vacancies on the services being provided to elderly and disabled people.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/2170", "label" : {"_value" : "Biography information for Lord Ouseley"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Ouseley"}
], "uin" : "HL133"}
, {"_about" : "http://data.parliament.uk/resources/730989", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/730989/answer", "answerText" : {"_value" : " The information requested is not held centrally.<\/p> <\/p> Core hours for general practices are defined in the General Medical Services and Personal Medical Services regulations, The National Health Service (General Medical Services Contracts and Personal Medical Services Agreements) (Amendment) Regulations 2016, SI 2016 No.875.<\/p> <\/p> Core hours are 8am \u2013 6:30pm Monday to Friday, except Good Friday, Christmas Day and bank holidays.<\/p> <\/p> The 2015-16 GP Patient Survey showed that 74.6% of patients reported that their general practitioner surgery was open at convenient times and that 75.9% were satisfied with the hours that their surgery opened.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-07-03", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-03T16:46:14.533Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-21", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "GP Surgeries: Opening Hours"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 3 February (HL4841), what was the average number of days that GP surgeries were open in the period 27\u201330 December 2016.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/2533", "label" : {"_value" : "Biography information for Lord Birt"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Birt"}
], "uin" : "HL14"}
, {"_about" : "http://data.parliament.uk/resources/731058", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/731058/answer", "answerText" : {"_value" : " The Government will work to address the challenges of social care for our ageing population, bringing forward proposals for consultation to build widespread support.<\/p> <\/p> We will provide further details on the next steps on social care in due course.<\/p> <\/strong><\/p> The Government is committed to listening to people\u2019s views on how to reform the social care system, to ensure it is sustainable for current and future generations and that the quality of care improves.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-07-03", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-03T11:42:12.763Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-21", "_datatype" : "dateTime"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government when they intend to bring forward proposals for a consultation on social care.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4290", "label" : {"_value" : "Biography information for Baroness Lawrence of Clarendon"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Lawrence of Clarendon"}
], "uin" : "HL66"}
, {"_about" : "http://data.parliament.uk/resources/731063", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/731063/answer", "answerText" : {"_value" : " The information on how many mentally ill people are currently in prison in England and Wales is not collected centrally. NHS England is currently carrying out a service review across all adult high, medium and low secure services in order to improve access, egress and throughput.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-07-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-05T12:19:13.993Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-21", "_datatype" : "dateTime"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government how many mentally ill people are currently in prison in England and Wales; what proportion of the prison population have mental illnesses; and what proposals they have to increase the number of beds in specialist hospitals for mentally ill patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/2170", "label" : {"_value" : "Biography information for Lord Ouseley"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Ouseley"}
], "uin" : "HL71"}
, {"_about" : "http://data.parliament.uk/resources/731066", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/731066/answer", "answerText" : {"_value" : " The Medicines and Healthcare products Regulatory Agency sets and charges fees for marketing authorisations in the United Kingdom which are granted nationally and not approved centrally by the European Medicines Agency. The extent to which European Medicines Agency procedures will apply in the UK after we have exited the European Union will be subject to negotiations. The Government will ensure that the UK\u2019s full approval regime is ready and operational as soon as the UK has formally departed the EU.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-06-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-06-29T11:37:19.147Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-21", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Drugs"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government whether they plan to convert EU Regulation 658/2014 into UK law; and, if so, which UK body will assume the role of the European Medicines Agency for the setting and charging of fees to UK-based marketing authorisation holders.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4159", "label" : {"_value" : "Biography information for Baroness Hayter of Kentish Town"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Hayter of Kentish Town"}
], "uin" : "HL74"}
, {"_about" : "http://data.parliament.uk/resources/731067", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/731067/answer", "answerText" : {"_value" : " The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation. As part of exit negotiations the Government will discuss with the European Union and Member States how best to continue cooperation in the field of clinical trials, including access to the EU portal and database.<\/p> <\/p> The UK applied sustained pressure to successfully reform the current Clinical Trials Directive in the best interests of patients and business and is planning for the new Clinical Trials Regulation to be brought onto our statute book. The timing of the application date of the new regulation is yet to be determined by the European Commission.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-06-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-06-29T11:38:11.057Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-21", "_datatype" : "dateTime"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government whether they plan to convert EU Regulation 536/2014 into UK law; and, if so, whether the UK will continue to notify the EU Clinical Trial Portal of applications for clinical trials for medicinal products for human use, and retain full access to the Portal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4159", "label" : {"_value" : "Biography information for Baroness Hayter of Kentish Town"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Hayter of Kentish Town"}
], "uin" : "HL75"}
, {"_about" : "http://data.parliament.uk/resources/731068", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/731068/answer", "answerText" : {"_value" : " The Department does not hold this information centrally.<\/p> <\/strong><\/p> Responsibility for ongoing post registration Professional Development lies with individual employers.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-04T15:10:37.073Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-21", "_datatype" : "dateTime"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government what change in funding in England for continued professional development for Registered Nurses took place in 2016/17; and what steps they are taking to address the situation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4566", "label" : {"_value" : "Biography information for Baroness Watkins of Tavistock"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Watkins of Tavistock"}
], "uin" : "HL76"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&houseId=2&AnsweringBody.=Department+of+Health&answer.answeringMemberPrinted=Lord+O%27Shaughnessy&max-answer.questionFirstAnswered.=2017-07-05T12%3A19%3A13.993Z", "page" : 0, "startIndex" : 1, "totalResults" : 301, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}